160 related articles for article (PubMed ID: 33036278)
1. Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide.
Zykova AA; Blokhina EA; Kotlyarov RY; Stepanova LA; Tsybalova LM; Kuprianov VV; Ravin NV
Viruses; 2020 Oct; 12(10):. PubMed ID: 33036278
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
3. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
4. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
5. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
8. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
[TBL] [Abstract][Full Text] [Related]
9. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
10. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.
Ni Y; Guo J; Turner D; Tizard I
Vaccine; 2017 Dec; 35(50):7026-7032. PubMed ID: 29102171
[TBL] [Abstract][Full Text] [Related]
12. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
13. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
14. Universal influenza A vaccine: optimization of M2-based constructs.
De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
[TBL] [Abstract][Full Text] [Related]
15. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
16. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
[TBL] [Abstract][Full Text] [Related]
17. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.
Zhao G; Miao Y; Guo Y; Qiu H; Sun S; Kou Z; Yu H; Li J; Chen Y; Jiang S; Du L; Zhou Y
Hum Vaccin Immunother; 2014; 10(12):3649-58. PubMed ID: 25483702
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.
Heinen PP; Rijsewijk FA; de Boer-Luijtze EA; Bianchi ATJ
J Gen Virol; 2002 Aug; 83(Pt 8):1851-1859. PubMed ID: 12124449
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles based on artificial self-assembling peptide and displaying M2e peptide and stalk HA epitopes of influenza A virus induce potent humoral and T-cell responses and protect against the viral infection.
Zykova AA; Blokhina EA; Stepanova LA; Shuklina MA; Tsybalova LM; Kuprianov VV; Ravin NV
Nanomedicine; 2022 Jan; 39():102463. PubMed ID: 34583058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
